| A Study of Efficacy and Safety of TLL-018 in CSU Participants With Inadequate Response to 2nd-generation H1-AHs (NCT07764003) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2026-09-10 |
| TLL-018 in Patients With Moderate to Severe Active Rheumatoid Arthritis With Inadequate Response or Intolerance to csDMARDs (NCT07748728) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2026-08-14 |
| A Phase Ib/IIa Study Assessing the Rapid Onset Characteristics of TLL-018 for Moderate-to-Severe CSU With Inadequate Response to Second-Generation H1 Antihistamines (NCT07665996) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2026-07-15 |
| HL-300 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (NCT07629778) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2026-05-26 |
| A Long-term Extension Clinical Study of TLL-018 in Patients With Rheumatoid Arthritis (NCT06887127) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2025-03-10 |
| HL-300 Ointment in Healthy Volunteers (NCT07684937) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2024-06-14 |
| A Study of Efficacy and Safety of TLL-018 in CSU Participants (NCT06396026) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2024-03-27 |
| A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs (NCT06020144) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2023-11-15 |
| Evaluation of TLL-018 Extended and Immediate Release Formulation for Bioequivalence Testing in Healthy Chinese Subjects (NCT05945810) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2023-07-12 |
| The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis (NCT05772520) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2023-01-19 |
| Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis (NCT05342428) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2022-06-10 |
| Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria. (NCT05373355) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2022-05-10 |
| The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis (NCT05133297) | Hangzhou Highlightll Pharmaceutical Co., Ltd | 2022-02-16 |